NCT03418350 The Role of Laryngopharyngeal Reflux in IPF
| NCT ID | NCT03418350 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Jewish Health |
| Condition | IPF |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2018-08-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2018-08-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of IPF * Age 40-95 * Able to read, speak, and understand English * If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent. Exclusion Criteria: * Patients who do not meet all inclusion criteria * Pregnant females
Contact & Investigator
Matthew Koslow, DO
PRINCIPAL INVESTIGATOR
National Jewish Health
Frequently Asked Questions
Who can join the NCT03418350 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 95 Years, studying IPF. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03418350 currently recruiting?
Yes, NCT03418350 is actively recruiting participants. Contact the research team at ILDresearch@njhealth.org for enrollment information.
Where is the NCT03418350 trial being conducted?
This trial is being conducted at Denver, United States.
Who is sponsoring the NCT03418350 clinical trial?
NCT03418350 is sponsored by National Jewish Health. The principal investigator is Matthew Koslow, DO at National Jewish Health. The trial plans to enroll 60 participants.